Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Stock Short Interest Report for October

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) saw a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 16,869 shares, a decrease of 91.4% from the October 15th total of 195,736 shares. Based on an average daily volume of 77,912 shares, the short-interest ratio is presently 0.2 days. Currently, 2.1% of the shares of the stock are sold short.

Hong Kong Pharma Digital Technology Price Performance

NASDAQ HKPD traded down $0.10 during trading hours on Thursday, reaching $1.53. 8,374 shares of the company’s stock were exchanged, compared to its average volume of 50,967. The firm has a fifty day moving average of $2.15 and a 200-day moving average of $8.73. The company has a quick ratio of 3.75, a current ratio of 3.86 and a debt-to-equity ratio of 0.01. Hong Kong Pharma Digital Technology has a one year low of $1.34 and a one year high of $29.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Hong Kong Pharma Digital Technology in a research report on Wednesday. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Hong Kong Pharma Digital Technology currently has an average rating of “Sell”.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.